{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:35:41Z","timestamp":1792690541943,"version":"4.5.0"},"reference-count":113,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T00:00:00Z","timestamp":1424908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0118341","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T18:51:18Z","timestamp":1424976678000},"page":"e0118341","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Carboxyl-Terminal Truncations Alter the Activity of the Human \u03b1-Galactosidase A"],"prefix":"10.1371","volume":"10","author":[{"given":"Mariam","family":"Meghdari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abass","family":"Abdullahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,2,26]]},"reference":[{"key":"ref1","first-page":"2741","article-title":"The Metabolic Basis of Inherited Disease","author":"RJ Desnick","year":"1995"},{"key":"ref2","first-page":"1045","article-title":"From cystases to lysosomes","volume":"23","author":"C De Duve","year":"1964","journal-title":"Federation Proceedings"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for gaucher\u2019s disease","volume":"324","author":"NW Barton","year":"1991","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1073\/pnas.87.5.1913","article-title":"Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with gaucher disease","volume":"87","author":"NW Barton","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1056\/NEJM199111073251906","article-title":"Gaucher\u2019s disease","volume":"325","author":"E Beutler","year":"1991","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood.V78.5.1183.1183","article-title":"Enzyme replacement therapy for gaucher disease","volume":"78","author":"E Beutler","year":"1991","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/humu.20524","article-title":"Type 1 gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring","volume":"28","author":"ME Grace","year":"2007","journal-title":"Hum Mutat"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in fabry\u2019s disease","volume":"345","author":"CM Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in fabry disease: a randomized controlled trial","volume":"285","author":"R Schiffmann","year":"2001","journal-title":"Jama"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"PB Deegan","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (gl-3) in urine from fabry patients during agalsidase beta therapy","volume":"92","author":"T Ohashi","year":"2007","journal-title":"Mol Genet Metab"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"R Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced fabry disease: a randomized trial","volume":"146","author":"M Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"RJ Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with fabry disease","volume":"18","author":"DP Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for fabry disease","volume":"75","author":"WR Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","article-title":"Enzyme replacement therapy in heterozygous females with fabry disease: results of a phase iiib study","volume":"26","author":"F Baehner","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of anderson-fabry disease in heterozygous females","volume":"40","author":"C Kampmann","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00467-006-0176-5","article-title":"Iga nephropathy in two adolescent sisters heterozygous for fabry disease","volume":"21","author":"C Whybra","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00431-009-0937-9","article-title":"Fabry disease in children and the effects of enzyme replacement treatment","volume":"168","author":"G Pintos-Morell","year":"2009","journal-title":"Eur J Pediatr"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric fabry disease","volume":"115","author":"M Ries","year":"2005","journal-title":"Pediatrics"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jpeds.2009.11.007","article-title":"Four-year prospective clinical trial of agalsidase alfa in children with fabry disease","volume":"156","author":"R Schiffmann","year":"2010","journal-title":"J Pediatr"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"S Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder fabry disease","volume":"13","author":"K Lee","year":"2003","journal-title":"Glycobiology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/glycob\/8.4.329","article-title":"Human alpha-galactosidase a: characterization of the n-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by chinese hamster ovary cells","volume":"8","author":"F Matsuura","year":"1998","journal-title":"Glycobiology"},{"issue":"Pt 3","key":"ref26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1042\/bj3320789","article-title":"Human alpha-galactosidase a: glycosylation site 3 is essential for enzyme solubility","volume":"332","author":"YA Ioannou","year":"1998","journal-title":"Biochem J"},{"key":"ref27","article-title":"Fabry Disease: Perspectives from 5 Years of FOS","volume":"Chapter 5","author":"S Bekri","year":"2006"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/glycob\/cwf096","article-title":"Production in yeast of alpha-galactosidase a, a lysosomal enzyme applicable to enzyme replacement therapy for fabry disease","volume":"12","author":"Y Chiba","year":"2002","journal-title":"Glycobiology"},{"key":"ref29","article-title":"Fabry Disease: Perspectives from 5 Years of FOS","volume":"chapter 43","author":"R Brady","year":"2006"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1875397301004010050","article-title":"Fabry disease\u2014current treatment and new drug development","volume":"4","author":"O Motabar","year":"2010","journal-title":"Curr Chem Genomics"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1006\/mthe.2002.0605","article-title":"Adenovirus-transduced lung as a portal for delivering alpha-galactosidase a into systemic circulation for fabry disease","volume":"5","author":"C Li","year":"2002","journal-title":"Mol Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/jgm.468","article-title":"Partial correction of the alpha-galactosidase a deficiency and reduction of glycolipid storage in fabry mice using synthetic vectors","volume":"6","author":"M Przybylska","year":"2004","journal-title":"J Gene Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40259-013-0032-7","article-title":"Gene therapy for fabry disease: a review of the literature","volume":"27","author":"AP Ruiz de Garibay","year":"2013","journal-title":"BioDrugs"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.gt.3302839","article-title":"Efficient correction of fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem\/progenitor cells","volume":"14","author":"M Yoshimitsu","year":"2007","journal-title":"Gene Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.mt.6300066","article-title":"Correction of the biochemical and functional deficits in fabry mice following aav8-mediated hepatic expression of alpha-galactosidase a","volume":"15","author":"RJ Ziegler","year":"2007","journal-title":"Mol Ther"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1089\/10430340252939041","article-title":"Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of fabry disease","volume":"13","author":"RJ Ziegler","year":"2002","journal-title":"Hum Gene Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"Aav2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase a and the induction of immune tolerance in fabry mice","volume":"9","author":"RJ Ziegler","year":"2004","journal-title":"Mol Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1089\/10430349950017671","article-title":"Correction of enzymatic and lysosomal storage defects in fabry mice by adenovirus-mediated gene transfer","volume":"10","author":"RJ Ziegler","year":"1999","journal-title":"Hum Gene Ther"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","article-title":"Improvement in cardiac function in the cardiac variant of fabry\u2019s disease with galactose-infusion therapy","volume":"345","author":"A Frustaci","year":"2001","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2007.05.082","article-title":"Screening for pharmacological chaperones in fabry disease","volume":"359","author":"SH Shin","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.braindev.2012.12.002","article-title":"Chaperone therapy update: Fabry disease, gm1-gangliosidosis and gaucher disease","volume":"35","author":"Y Suzuki","year":"2013","journal-title":"Brain Dev"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e15033","DOI":"10.1371\/journal.pone.0015033","article-title":"Substrate reduction augments the efficacy of enzyme therapy in a mouse model of fabry disease","volume":"5","author":"J Marshall","year":"2010","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S1474-4422(04)00938-X","article-title":"Enzyme-replacement therapy for metabolic storage disorders","volume":"3","author":"RO Brady","year":"2004","journal-title":"Lancet Neurol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/B:BOLI.0000031101.12838.c6","article-title":"Enzyme replacement and enhancement therapies for lysosomal diseases","volume":"27","author":"RJ Desnick","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00003495-200262050-00002","article-title":"New prospects for the treatment of lysosomal storage diseases","volume":"62","author":"R Schiffmann","year":"2002","journal-title":"Drugs"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges","volume":"13","author":"RJ Desnick","year":"2012","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrneurol.2013.163","article-title":"Lysosomal storage diseases\u2013the horizon expands","volume":"9","author":"RM Boustany","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0378-1119(87)90119-3","article-title":"Expression of the human alpha-galactosidase a in escherichia coli k-12","volume":"57","author":"PA Hantzopoulos","year":"1987","journal-title":"Gene"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1006\/prep.2000.1284","article-title":"Purification and characterization of human alpha-galactosidase a expressed in insect cells using a baculovirus vector","volume":"20","author":"Y Chen","year":"2000","journal-title":"Protein Expr Purif"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0378-1119(94)90378-6","article-title":"Characterization of glycosylated and catalytically active recombinant human alpha-galactosidase a using a baculovirus vector","volume":"144","author":"G Coppola","year":"1994","journal-title":"Gene"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1083\/jcb.119.5.1137","article-title":"Overexpression of human alpha-galactosidase a results in its intracellular aggregation, crystallization in lysosomes, and selective secretion","volume":"119","author":"YA Ioannou","year":"1992","journal-title":"J Cell Biol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase a reduces tissue globotriaosylceramide storage in patients with fabry disease","volume":"97","author":"R Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1006\/prep.2000.1325","article-title":"Expression and characterization of glycosylated and catalytically active recombinant human alpha-galactosidase a produced in pichia pastoris","volume":"20","author":"Y Chen","year":"2000","journal-title":"Protein Expr Purif"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10038-006-0369-6","article-title":"Corrective effect on fabry mice of yeast recombinant human alpha-galactosidase with n-linked sugar chains suitable for lysosomal delivery","volume":"51","author":"H Sakuraba","year":"2006","journal-title":"J Hum Genet"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0958-1669(02)00330-0","article-title":"Production of recombinant proteins in fermenter cultures of the yeast pichia pastoris","volume":"13","author":"GP Cereghino","year":"2002","journal-title":"Curr Opin Biotechnol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/yea.1208","article-title":"Heterologous protein production using the pichia pastoris expression system","volume":"22","author":"S Macauley-Patrick","year":"2005","journal-title":"Yeast"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/jmr.687","article-title":"Expression of heterologous proteins in pichia pastoris: a useful experimental tool in protein engineering and production","volume":"18","author":"R Daly","year":"2005","journal-title":"J Mol Recognit"},{"key":"ref58","article-title":"Molecular Cell Biology","author":"H Lodish","year":"2000"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/prep.1998.0933","article-title":"Variation in n-linked oligosaccharide structures on heterologous proteins secreted by the methylotrophic yeast pichia pastoris","volume":"14","author":"R Montesino","year":"1998","journal-title":"Protein Expr Purif"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1073\/pnas.76.10.5326","article-title":"Enzyme therapy in fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase a isozymes","volume":"76","author":"RJ Desnick","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1590\/S1415-47572012000600009","article-title":"Enzyme replacement therapy for fabry disease: A systematic review and meta-analysis","volume":"35","author":"T Alegra","year":"2012","journal-title":"Genet Mol Biol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nrg963","article-title":"Enzyme replacement and enhancement therapies: lessons from lysosomal disorders","volume":"3","author":"RJ Desnick","year":"2002","journal-title":"Nat Rev Genet"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1172\/JCI118981","article-title":"A carboxy-terminal truncation of human alpha-galactosidase a in a heterozygous female with fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted","volume":"98","author":"N Miyamura","year":"1996","journal-title":"J Clin Invest"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF02942184","article-title":"Fermentation strategies for recombinant protein expression in the methylotrophic yeast pichia pastoris","volume":"5","author":"W Zhang","year":"2000","journal-title":"Biotechnol Bioprocess Eng"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.pep.2004.07.005","article-title":"Efficient and rapid purification of recombinant human alpha-galactosidase a by affinity column chromatography","volume":"37","author":"K Yasuda","year":"2004","journal-title":"Protein Expr Purif"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.chroma.2007.03.126","article-title":"Elution of tightly bound solutes from concanavalin a sepharose. factors affecting the desorption of cottonmouth venom glycoproteins","volume":"1154","author":"AS Soper","year":"2007","journal-title":"J Chromatogr A"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2144\/00283bm07","article-title":"Heating greatly speeds coomassie blue staining and destaining","volume":"28","author":"C Wong","year":"2000","journal-title":"Biotechniques"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1006\/abio.1993.1504","article-title":"A fluorescence-based protein assay for use with a microplate reader","volume":"214","author":"A Lorenzen","year":"1993","journal-title":"Anal Biochem"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0021-9258(19)69965-5","article-title":"Affinity purification of alpha-galactosidase a from human spleen, placenta, and plasma with elimination of pyrogen contamination. properties of the purified splenic enzyme compared to other forms","volume":"256","author":"DF Bishop","year":"1981","journal-title":"J Biol Chem"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.chembiol.2011.10.012","article-title":"The molecular basis of pharmacological chaperoning in human alpha-galactosidase","volume":"18","author":"AI Guce","year":"2011","journal-title":"Chem Biol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0076-6879(55)01020-3","article-title":"Preparation of buffers for use in enzyme studies","volume":"1","author":"G Gomori","year":"1955","journal-title":"Methods Enzymol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/bioinformatics\/btq007","article-title":"Pyrosetta: a script-based interface for implementing molecular modeling algorithms using rosetta","volume":"26","author":"S Chaudhury","year":"2010","journal-title":"Bioinformatics"},{"key":"ref73","unstructured":"Schr\u00f6dinger, LLC (2010) The PyMOL molecular graphics system, version 1.3r1."},{"key":"ref74","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nprot.2009.2","article-title":"Protein structure prediction on the web: a case study using the phyre server","volume":"4","author":"LA Kelley","year":"2009","journal-title":"Nat Protoc"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"7364","DOI":"10.1073\/pnas.82.21.7364","article-title":"Fabry disease: isolation of a cdna clone encoding human alpha-galactosidase a","volume":"82","author":"DH Calhoun","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0925-4439(00)00024-7","article-title":"Characterization of two alpha-galactosidase mutants (q279e and r301q) found in an atypical variant of fabry disease","volume":"1501","author":"R Kase","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1016\/S0021-9258(19)44613-9","article-title":"Purification and properties of human alpha-galactosidases","volume":"247","author":"E Beutler","year":"1972","journal-title":"J Biol Chem"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"9994","DOI":"10.1016\/S0021-9258(19)86663-2","article-title":"Studies on human liver alpha-galactosidases. i. purification of alpha-galactosidase a and its enzymatic properties with glycolipid and oligosaccharide substrates","volume":"254","author":"KJ Dean","year":"1979","journal-title":"J Biol Chem"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of ph and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"RL Lieberman","year":"2009","journal-title":"Biochemistry"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0021-9258(17)38286-8","article-title":"Purification and properties of the two major isozymes of alpha-galactosidase from human placenta","volume":"253","author":"JW Kusiak","year":"1978","journal-title":"J Biol Chem"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1006\/abbi.2000.1743","article-title":"Role of ser-65 in the activity of alpha-galactosidase a: characterization of a point mutation (s65t) detected in a patient with fabry disease","volume":"377","author":"S Ishii","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2008.12.017","article-title":"Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in fabry disease","volume":"96","author":"K Sugawara","year":"2009","journal-title":"Mol Genet Metab"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant alpha-galactosidase a enzymes identified in fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"S Ishii","year":"2007","journal-title":"Biochem J"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2011.01.013","article-title":"Molecular mechanism for stabilization of a mutant alpha-galactosidase a involving m51i amino acid substitution by imino sugars","volume":"103","author":"T Tsukimura","year":"2011","journal-title":"Mol Genet Metab"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1074\/jbc.M109.060145","article-title":"Catalytic mechanism of human alpha-galactosidase","volume":"285","author":"AI Guce","year":"2010","journal-title":"J Biol Chem"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and gl-3","volume":"94","author":"AC Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","article-title":"A revised home treatment algorithm for fabry disease: influence of antibody formation","volume":"108","author":"BE Smid","year":"2013","journal-title":"Mol Genet Metab"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"GE Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","article-title":"Reduced alpha-gal a enzyme activity in fabry fibroblast cells and fabry mice tissues induced by serum from antibody positive patients with fabry disease","volume":"94","author":"T Ohashi","year":"2008","journal-title":"Mol Genet Metab"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10545-012-9472-3","article-title":"Lysosomal delivery of therapeutic enzymes in cell models of fabry disease","volume":"35","author":"D Marchesan","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"alpha-galactosidase a deficient mice: a model of fabry disease","volume":"94","author":"T Ohshima","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BJ20130825","article-title":"A symptomatic fabry disease mouse model generated by inducing globotriaosylceramide synthesis","volume":"456","author":"A Taguchi","year":"2013","journal-title":"Biochem J"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1021\/bi00670a032","article-title":"Evolution of enzyme function and the development of catalytic efficiency","volume":"15","author":"WJ Albery","year":"1976","journal-title":"Biochemistry"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to fabry disease: structure of human alpha-galactosidase","volume":"337","author":"SC Garman","year":"2004","journal-title":"J Mol Biol"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"21560","DOI":"10.1074\/jbc.M110.118588","article-title":"Interconversion of the specificities of human lysosomal enzymes associated with fabry and schindler diseases","volume":"285","author":"IB Tomasic","year":"2010","journal-title":"J Biol Chem"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0304-4165(76)90017-9","article-title":"Properties of mouse alpha-galactosidase","volume":"437","author":"AJ Lusis","year":"1976","journal-title":"Biochim Biophys Acta"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.resmic.2011.10.005","article-title":"Aga1, the first alpha-galactosidase from the human bacteria ruminococcus gnavus e1, efficiently transcribed in gut conditions","volume":"163","author":"M Aguilera","year":"2012","journal-title":"Res Microbiol"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00253-004-1764-6","article-title":"Purification, cloning, and properties of alpha-galactosidase from saccharopolyspora erythraea and its use as a reporter system","volume":"67","author":"DA Post","year":"2005","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"28020","DOI":"10.1074\/jbc.M110.144584","article-title":"Structural analysis of saccharomyces cerevisiae alpha-galactosidase and its complexes with natural substrates reveals new insights into substrate specificity of gh27 glycosidases","volume":"285","author":"R Fernandez-Leiro","year":"2010","journal-title":"J Biol Chem"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1128\/JB.184.2.600-604.2002","article-title":"alpha-galactosidase aga27a, an enzymatic component of the clostridium josui cellulosome","volume":"184","author":"S Jindou","year":"2002","journal-title":"J Bacteriol"},{"issue":"Pt 1","key":"ref101","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1042\/bj3390043","article-title":"Lignocellulose degradation by phanerochaete chrysosporium: purification and characterization of the main alpha-galactosidase","volume":"339","author":"H Brumer r","year":"1999","journal-title":"Biochem J"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"D490","DOI":"10.1093\/nar\/gkt1178","article-title":"The carbohydrate-active enzymes database (cazy) in 2013","volume":"42","author":"V Lombard","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/abbi.1999.1532","article-title":"The carboxyl terminus of coffee bean alpha-galactosidase is critical for enzyme activity","volume":"373","author":"E Maranville","year":"2000","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02374-10","article-title":"Sequential deletion of the integrase (gag-pol) carboxyl terminus reveals distinct phenotypic classes of defective hiv-1","volume":"85","author":"KD Mohammed","year":"2011","journal-title":"J Virol"},{"issue":"Pt 8","key":"ref105","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1099\/0022-1317-77-8-1893","article-title":"Functional analysis of c-terminal deletion mutants of epstein-barr virus thymidine kinase","volume":"77","author":"TY Hsu","year":"1996","journal-title":"J Gen Virol"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.abb.2005.08.010","article-title":"Deletion mutation analysis on c-terminal domain of plant vacuolar h(+)-pyrophosphatase","volume":"442","author":"HH Lin","year":"2005","journal-title":"Arch Biochem Biophys"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0065-2571(64)80018-2","article-title":"The role of phosphofructokinase in metabolic regulation","volume":"2","author":"JV Passonneau","year":"1964","journal-title":"Adv Enzyme Regul"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/iub.393","article-title":"Regulation of mammalian muscle type 6-phosphofructo-1-kinase and its implication for the control of the metabolism","volume":"62","author":"M Sola-Penna","year":"2010","journal-title":"IUBMB Life"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1126\/science.1085515","article-title":"A perspective on enzyme catalysis","volume":"301","author":"SJ Benkovic","year":"2003","journal-title":"Science"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1021\/ja031683w","article-title":"Tunneling and coupled motion in the escherichia coli dihydrofolate reductase catalysis","volume":"126","author":"RS Sikorski","year":"2004","journal-title":"J Am Chem Soc"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"15753","DOI":"10.1073\/pnas.0606976103","article-title":"Coordinated effects of distal mutations on environmentally coupled tunneling in dihydrofolate reductase","volume":"103","author":"L Wang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1098\/rstb.2006.1871","article-title":"The role of enzyme dynamics and tunnelling in catalysing hydride transfer: studies of distal mutants of dihydrofolate reductase","volume":"361","author":"L Wang","year":"2006","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1021\/bi0518242","article-title":"Effects of a distal mutation on active site chemistry","volume":"45","author":"L Wang","year":"2006","journal-title":"Biochemistry"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0118341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T22:21:26Z","timestamp":1651357286000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0118341"}},"subtitle":[],"editor":[{"given":"Stephan Neil","family":"Witt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,2,26]]},"references-count":113,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0118341","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,26]]}}}